An analysis of the safety profile of proteasome inhibitors for treating various cancers.

about

Fatal pulmonary toxicity due to carfilzomib (Kyprolis™).Next-generation proteasome inhibitor oprozomib synergizes with modulators of the unfolded protein response to suppress hepatocellular carcinoma.TRAIL mediates and sustains constitutive NF-κB activation in LGL leukemia.

P2860

Q41184318-E5EC3F3C-F0EB-493B-8347-8C3833457591 Q41610374-5E895E85-EBDD-4C32-98F7-3FBFA5741A4B Q52716419-34442CDD-5583-4B9E-A461-14FDFF19AE24

P2860

An analysis of the safety profile of proteasome inhibitors for treating various cancers.

Item

http://www.wikidata.org/entity/Q38227506

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

An analysis of the safety profile of proteasome inhibitors for treating various cancers.

@en

type

Item

label

An analysis of the safety profile of proteasome inhibitors for treating various cancers.

@en

prefLabel

An analysis of the safety profile of proteasome inhibitors for treating various cancers.

@en

P1476

An analysis of the safety profile of proteasome inhibitors for treating various cancers.

@en

P2093

Di Chen

http://www.w3.org/2001/XMLSchema#string

Fangxia Guan

http://www.w3.org/2001/XMLSchema#string

Huanjie Yang

http://www.w3.org/2001/XMLSchema#string

Hui Wang

http://www.w3.org/2001/XMLSchema#string

Qing Ping Dou

http://www.w3.org/2001/XMLSchema#string

P2860

New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG)

Regulation of CD8+ T cell development by thymus-specific proteasomes

Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis

The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma

The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B

Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies.

A phase 2 study of bortezomib in relapsed, refractory myeloma.

A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma.

Bortezomib-induced severe hepatitis in multiple myeloma: a case report.

A practical update on the use of bortezomib in the management of multiple myeloma.

P304

1043-1054

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14740338.2014.939953

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2014-07-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25005844

http://www.w3.org/2001/XMLSchema#string

An analysis of the safety profile of proteasome inhibitors for treating various cancers.

about

P2860

P2860

An analysis of the safety profile of proteasome inhibitors for treating various cancers.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698